TY - JOUR
T1 - Salvage therapies in relapsed and/or refractory myeloma
T2 - What is current and what is the future?
AU - Thumallapally, Nishitha
AU - Yu, Hana
AU - Asti, Divya
AU - Vennepureddy, Adarsh
AU - Terjanian, Terenig
N1 - Publisher Copyright:
© 2016 Thumallapally et al.
PY - 2016/8/5
Y1 - 2016/8/5
N2 - The treatment landscape for multiple myeloma (MM) is evolving with our understanding of its pathophysiology. However, given the inevitable cohort heterogeneity in salvage therapy, response to treatment and overall prognoses tend to vary widely, making meaningful conclusions about treatment efficacy difficult to derive. Despite the hurdles in current research, progress is underway toward more targeted therapeutic approaches. Several new drugs with novel mechanism of action and less toxic profile have been developed in the past decade, with the potential for use as single agents or in synergy with other treatment modalities in MM therapy. As our discovery of these emerging therapies progresses, so too does our need to reshape our knowledge on knowing how to apply them. This review highlights some of the recent landmark changes in MM management with specific emphasis on salvage drugs available for relapsed and refractory MM and also discusses some of the upcoming cutting-edge therapies that are currently in various stages of clinical development.
AB - The treatment landscape for multiple myeloma (MM) is evolving with our understanding of its pathophysiology. However, given the inevitable cohort heterogeneity in salvage therapy, response to treatment and overall prognoses tend to vary widely, making meaningful conclusions about treatment efficacy difficult to derive. Despite the hurdles in current research, progress is underway toward more targeted therapeutic approaches. Several new drugs with novel mechanism of action and less toxic profile have been developed in the past decade, with the potential for use as single agents or in synergy with other treatment modalities in MM therapy. As our discovery of these emerging therapies progresses, so too does our need to reshape our knowledge on knowing how to apply them. This review highlights some of the recent landmark changes in MM management with specific emphasis on salvage drugs available for relapsed and refractory MM and also discusses some of the upcoming cutting-edge therapies that are currently in various stages of clinical development.
KW - Multiple myeloma
KW - Novel drugs
KW - Relapsed and refractory myeloma
KW - Salvage chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=84988688653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988688653&partnerID=8YFLogxK
U2 - 10.2147/OTT.S110189
DO - 10.2147/OTT.S110189
M3 - Review article
C2 - 27540299
AN - SCOPUS:84988688653
SN - 1178-6930
VL - 9
SP - 4843
EP - 4858
JO - OncoTargets and Therapy
JF - OncoTargets and Therapy
ER -